Theseus Pharmaceuticals, Inc.
Save
181.50M
Market cap
Current P/E
Forward P/E

About

Health care
Sector
Biotechnology
Industry

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer.

Similar securities

Based on sector and market capitalization

Report issue